Treatment of dialysis catheter infections in 2004

Journal of Vascular Access

Volumn 5, Issue 3, 2004, Pages 99-108

  Gersch, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antibiotic lock; Catheter; Dialysis; Guidewire; Infection; Tunneled

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CITRIC ACID; GENTAMICIN; HEPARIN; MINOCYCLINE; POLYSPORIN; PSEUDOMONIC ACID; RIFAMPICIN; TAUROLIDINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTERIOVENOUS FISTULA; BACTEREMIA; CATHETER INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVICE REMOVAL; DRUG PREFERENCE; GUIDE WIRE; HEMODIALYSIS; HUMAN; INFECTION CONTROL; INFECTION RISK; KIDNEY FAILURE; METASTASIS; MORBIDITY; MORTALITY; OTOTOXICITY; PATIENT REFERRAL; REVIEW; RISK REDUCTION; SEPSIS; VASCULAR ACCESS; VASCULAR SURGERY; VESTIBULAR DISORDER;

EID: 18844400566     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980400500303     Document Type: Review

References (90)

1. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999; 56: 1-17.
2. Saad TF. Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001; 14: 446-51.
3. Nassar GM, Ayus JC. Infectious complications of the hemodialysis access. Kidney Int 2001; 60: 1-13.
4. Oliver MJ, Schwab SJ. The role of guidewire exchange in the treatment of hemodialysis catheter related bloodstream infection. Int J Artif Organs 2001; 24: 179-82.
5. Kovalik EC, Schwab SJ. Treatment approaches for infected hemodialysis vascular catheters. Curr Opin Nephrol Hypertens 2002; 11: 593-6.
6. Fatkenheuer G, Cornely O, Seifert H. Clinical management of catheter-related infections. Clin Microbiol Infect 2002; 8: 545-50.
7. Ryan SV, Calligaro KD, Dougherty MJ. Management of hemodialysis access infections. Semin Vasc Surg 2004; 17: 40-4.
8. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37: S137-81.
9. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
10. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant 2002; 17 (suppl 7): 72-87.
11. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35: 603-10.
12. Combe C, Pisoni RL, Port FK, et al. Dialysis Outcomes and Practice Patterns Study: data on the use of central venous catheters in chronic hemodialysis. Nephrologie 2001; 22: 379-84.
13. Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305-16.
14. Reddan D, Klassen P, Frankenfield DL, et al. National profile of practice patterns for hemodialysis vascular access in the United States. J Am Soc Nephrol 2002; 13: 2117-24.
15. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-76.
16. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3: 201-7.
17. Raad I. Intravascular-catheter-related infections. Lancet 1998; 351: 893-8.
18. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15: 477-86.
19. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62: 620-6.
20. Moss AH, Vasilakis C, Holley JL, Foulks CJ, Pillai K, McDowell DE. Use of a silicone dual-lumen catheter with a Dacron cuff as a long-term vascular access for hemodialysis patients. Am J Kidney Dis 1990; 16: 211-5.
21. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127: 275-80.
22. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10: 1045-9.
23. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34: 1114-24.
24. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993; 64: 95-100.
25. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2003. Ref Type: Report.
26. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998; 54: 1684-9.
27. Mokrzycki MH, Singhal A. Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias. Nephrol Dial Transplant 2002; 17: 2196-203.
28. Vanherweghem JL, Cabolet P, Dhaene M, et al. Complications related to subclavian catheters for hemodialysis. Report and review. Am J Nephrol 1986; 6: 339-45.
29. Barrett N, Spencer S, McIvor J, Brown EA. Subclavian stenosis: a major complication of subclavian dialysis catheters. Nephrol Dial Transplant 1988; 3: 423-5.
30. Clark DD, Albina JE, Chazan JA. Subclavian vein stenosis and thrombosis: a potential serious complication in chronic hemodialysis patients. Am J Kidney Dis 1990; 15: 265-8.
31. Khanna S, Sniderman K, Simons M, Besley M, Uldall R. Superior vena cava stenosis associated with hemodialysis catheters. Am J Kidney Dis 1993; 21: 278-81.
32. Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transplant 1999; 14: 1710-4.
33. Ash SR. The evolution and function of central venous catheters for dialysis. Semin Dial 2001; 14: 416-24.
34. Conz PA. Permanent vascular catheters: Effectiveness and duration of the Ash-Split Cath. G Ital Nefrol 2003; 20 (suppl 22): S35-7.
35. Richard HM, III, Hastings GS, Boyd-Kranis RL, et al. A randomized, prospective evaluation of the Tesio, Ash split, and Opti-flow hemodialysis catheters. J Vasc Interv Radiol 2001; 12: 431-5.
36. McDowell DE, Moss AH, Vasilakis C, Bell R, Pillai L. Percutaneously placed dual-lumen silicone catheters for long-term hemodialysis. Am Surg 1993; 59: 569-73.
37. Thodis E, Passadakis P, Ossareh S, Panagoutsos S, Vargemezis V, Oreopoulos DG. Peritoneal catheter exit-site infections: predisposing factors, prevention and treatment. Int J Artif Organs 2003; 26: 698-714.
38. Hirsch DJ, Jindal KK. Local care of Staphylococcus aureus exit-site infection precludes antibiotic use. Perit Dial Int 2003; 23: 301-2.
39. Fowler VG, Jr., Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27: 478-86.
40. Kovalik EC, Raymond JR, Albers FJ, et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. J Am Soc Nephrol 1996; 7: 2264-7.
41. Raad I, Davis S, Khan A, Tarrand J, Elting L, Bodey GP. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992; 13: 215-21.
42. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990; 69: 296-306.
43. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore). 1995; 74: 340-9.
44. Pascual A. Pathogenesis of catheter-related infections: lessons for new designs. Clin Microbiol Infect 2002; 8: 256-64.
45. Vas SI. Infections related to prosthetic materials in patients on chronic dialysis. Clin Microbiol Infect 2002; 8: 705-8.
46. Dasgupta MK. Biofilms and infection in dialysis patients. Semin Dial 2002; 15: 338-46.
47. Holmes CJ. Catheter-associated biofilm. Contrib Nephrol 1990; 85: 49-56.
48. Trautner BW, Darouiche RO. Catheter-associated infections: pathogenesis affects prevention. Arch Intern Med 2004; 164: 842-50.
49. Passerini L, Lam K, Costerton JW, King EG. Biofilms on indwelling vascular catheters. Crit Care Med 1992; 20: 665-73.
50. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
51. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
52. Stewart PS. Biofilm accumulation model that predicts antibiotic resistance of Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 1994; 38: 1052-8.
53. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112: 1466-77.
54. Bastani B, Minton J, Islam S. Insufficient penetration of systemic vancomycin into the PermCath lumen. Nephrol Dial Transplant 2000; 15: 1035-7.
55. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12: 185-9.
56. Messing B. Catheter-sepsis during home parenteral nutrition: use of the antibiotic-lock technique. Nutrition 1998; 14: 466-8.
57. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12: 185-9.
58. Carratala J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin Microbiol Infect 2002; 8: 282-9.
59. Kim SH, Kang CI, Kim HB, et al. Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003; 24: 897-904.
60. Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993; 8: 231-4.
61. Vercaigne LM, Zelenitsky SA, Findlay I, Bernstein K, Penner SB. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49: 693-6.
62. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61: 1136-42.
63. Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant 2004; 19: 1237-44.
64. Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995; 25: 593-6.
65. Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int 1998; 53: 1792-4.
66. Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int 2000; 57: 2151-5.
67. Mokrzycki MH, Singhal A. Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias. Nephrol Dial Transplant 2002; 17: 2196-203.
68. Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002; 8: 275-81.
69. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. J Clin Microbiol 1988; 26: 1257-62.
70. Vanherweghem JL, Dhaene M, Goldman M, et al. Infections associated with subclavian dialysis catheters: the key role of nurse training. Nephron 1986; 42: 116-9.
71. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003; 14: 169-79.
72. Sesso R, Barbosa D, Leme IL, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol 1998; 9: 1085-92.
73. Johnson DW, MacGinley R, Kay TD, et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17: 1802-7.
74. Boelaert JR, Van Landuyt HW, De Baere YA, et al. Epidemiology and prevention of Staphylococcus aureus infections during hemodialysis. Nephrologie 1994; 15: 157-61.
75. Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage. Ann Pharmacother 1998; 32: S7-16.
76. Pratt O. An integrated critique of the efficacy of topical mupirocin in preventing catheter-related Staphylococcus aureus infections in peritoneal dialysis clients. CANNT J 2002; 12: 20-8.
77. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-9.
78. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect 1991; 19 (suppl B): S41-6.
79. Boelaert JR, De Smedt RA, De Baere YA, et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278-81.
80. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13: 2133-9.
81. Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36: 1539-44.
82. Betjes MG, Van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19: 1546-51.
83. Chatzinikolaou I, Hanna H, Graviss L, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol 2003; 24: 961-3.
84. Darouiche RO, Smith JA, Jr., Hanna H, et al. Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial. Urology 1999; 54: 976-81.
85. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999; 340: 1-8.
86. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127: 267-74.
87. Raad I, Buzaid A, Rhyne J, et al. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997; 25: 149-51.
88. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173: 418-24.
89. Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003; 115: 352-7.
90. Schwab SJ, Weiss MA, Rushton F, et al. Multicenter clinical trial results with the LifeSite hemodialysis access system. Kidney Int 2002; 62: 1026-33.